Roche-Denali Brain Shuttle gantenerumab (Trontinemab / RG6102, NCT04374253) program scope reflects BBB-transcytosis-as-delivery-target architecture; following Montagne 2020 APOE4-stratified BBB evidence, program decision-making prioritizes APOE4-stratified PK/PD readouts and BBB-permeability biomarker integration.

Evidence span

Roche-Denali Brain Shuttle gantenerumab (Trontinemab / RG6102, NCT04374253) program scope reflects BBB-transcytosis-as-delivery-target architecture; following Montagne 2020 APOE4-stratified BBB evidence, program decision-making prioritizes APOE4-stratified PK/PD readouts and BBB-permeability biomarker integration.

Method & conditions

Evidence type

observational

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Human, mild-moderate Alzheimer's disease. Bispecific antibody binding TfR (Brain Shuttle) and amyloid-β. Phase Ib pharmacokinetics + brain exposure.

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required